[go: up one dir, main page]

MX2018004351A - Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject. - Google Patents

Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject.

Info

Publication number
MX2018004351A
MX2018004351A MX2018004351A MX2018004351A MX2018004351A MX 2018004351 A MX2018004351 A MX 2018004351A MX 2018004351 A MX2018004351 A MX 2018004351A MX 2018004351 A MX2018004351 A MX 2018004351A MX 2018004351 A MX2018004351 A MX 2018004351A
Authority
MX
Mexico
Prior art keywords
ischemia
subject
medications
risk
prevent
Prior art date
Application number
MX2018004351A
Other languages
Spanish (es)
Other versions
MX391926B (en
Inventor
Vrabec Tamara
Original Assignee
Vrabec Tamara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrabec Tamara filed Critical Vrabec Tamara
Publication of MX2018004351A publication Critical patent/MX2018004351A/en
Publication of MX391926B publication Critical patent/MX391926B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proveen métodos de tratamiento y prevención del daño por isquemia-reperfusión e el daño relacionado con hipoxia intermitente crónica mediante la administración de un compuesto neuroprotector; al sujeto que se beneficiaría del método de la invención se le puede prescribir o someter a un tratamiento anti-VEGF, por ejemplo, un régimen de tratamiento IVAV, o puede tener un diagnóstico de un trastorno como apnea del sueño.Methods of treatment and prevention of ischemia-reperfusion damage and damage related to chronic intermittent hypoxia are provided by administration of a neuroprotective compound; The subject who would benefit from the method of the invention may be prescribed or subjected to an anti-VEGF treatment, for example, an IVAV treatment regimen, or may have a diagnosis of a disorder such as sleep apnea.

MX2018004351A 2015-10-09 2016-10-11 USE OF MEDICINES WITH NEUROPROTECTIVE PROPERTIES TO PREVENT OR REDUCE THE RISK OF ISCHEMIA-REPERFUSION DAMAGE IN A SUBJECT. MX391926B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562239639P 2015-10-09 2015-10-09
US15/193,625 US10105371B2 (en) 2015-10-09 2016-06-27 Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
PCT/US2016/056341 WO2017062974A1 (en) 2015-10-09 2016-10-11 Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject

Publications (2)

Publication Number Publication Date
MX2018004351A true MX2018004351A (en) 2019-01-10
MX391926B MX391926B (en) 2025-03-21

Family

ID=58488718

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004351A MX391926B (en) 2015-10-09 2016-10-11 USE OF MEDICINES WITH NEUROPROTECTIVE PROPERTIES TO PREVENT OR REDUCE THE RISK OF ISCHEMIA-REPERFUSION DAMAGE IN A SUBJECT.
MX2022004837A MX2022004837A (en) 2015-10-09 2018-04-09 Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004837A MX2022004837A (en) 2015-10-09 2018-04-09 Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject.

Country Status (8)

Country Link
US (3) US10105371B2 (en)
EP (1) EP3359257B1 (en)
JP (3) JP7071269B2 (en)
CN (2) CN108601950A (en)
BR (1) BR112018007139A2 (en)
CA (1) CA3001464A1 (en)
MX (2) MX391926B (en)
WO (1) WO2017062974A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
CN110974828B (en) * 2019-12-24 2023-03-31 苏州大学 Application of compound Axitinib in preparation of medicine for treating cerebrovascular diseases and pharmaceutical composition of compound Axitinib
CN113134116B (en) * 2020-01-20 2022-09-06 山东威高宏瑞医学科技有限公司 Filling composition and filling preparation for endoscopic minimally invasive surgery
CN115066232B (en) 2020-02-06 2024-12-10 视尔普斯眼科公司 Compositions and methods for treating eye diseases
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
KR102485499B1 (en) * 2022-07-15 2023-01-09 오가노이드사이언스 주식회사 Composition for treating or preventing kidney disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854207B1 (en) * 2007-04-04 2008-08-26 성공제 Agmatine for Retinal Ganglion Cell Protection
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
KR20180021741A (en) * 2015-05-29 2018-03-05 에쥐 세라피틱스, 인코포레이티드 Compositions and methods for reducing visual loss
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject

Also Published As

Publication number Publication date
MX2022004837A (en) 2022-05-16
US10105371B2 (en) 2018-10-23
US20210299142A1 (en) 2021-09-30
JP2024103501A (en) 2024-08-01
US12083128B2 (en) 2024-09-10
EP3359257B1 (en) 2025-05-28
JP2022107631A (en) 2022-07-22
CN116211871A (en) 2023-06-06
CA3001464A1 (en) 2017-04-13
US20190038636A1 (en) 2019-02-07
EP3359257A1 (en) 2018-08-15
JP2018530616A (en) 2018-10-18
WO2017062974A1 (en) 2017-04-13
US11033557B2 (en) 2021-06-15
MX391926B (en) 2025-03-21
CN108601950A (en) 2018-09-28
BR112018007139A2 (en) 2018-11-06
JP7071269B2 (en) 2022-05-18
US20170100410A1 (en) 2017-04-13
EP3359257A4 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
MX2018004351A (en) Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2016015997A (en) Preparation and use of crystalline beta-d-nicotinamide riboside.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2016010854A (en) METHODS FOR THE TREATMENT OR PREVENTION OF ASTHMA THROUGH THE ADMINISTRATION OF AN IL-4R ANTAGONIST.
PH12017500153B1 (en) Compositions and methods of use for treating metabolic disorders
MX390084B (en) P2X3 AND P2X2/3 DIAMINOPYRIMIDINE RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH.
NI201500150A (en) CANCER TREATMENT WITH DIHYDROPIRAZINE-PIRAZINES × Provided in this method
EA201591758A1 (en) Sub-ADAMTS13 INTRODUCTION
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
MX2022006770A (en) Bendamustine solid dispersions and continuous infusion.
CY1121566T1 (en) NEUROPROTECTIVE AND INDICATION OF THIS
MX2016011881A (en) Dry-powder peptide medicament.
BR112016016932A2 (en) TREATMENT OF NEOPLASIA
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
AR100734A1 (en) METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
BR112016012248A2 (en) nephropathy treatment method
IL250708A0 (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
MX2017014463A (en) Cabazitaxel and its use for treating cancer.
MX2016006882A (en) Infant nutrition for improvement in insulin sensitivity later in life.
MX384453B (en) IN VITRO METHODS FOR IDENTIFYING PREMATURE INFANTS AT RISK FOR BRONCHOPULMONARY DYSPLASIA.
AR098670A1 (en) SGLT1 INHIBITOR
NZ725303A (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer